RxDoctor Payments Data

Gerald Stinson

Optometrist · Lexington, MSNPI 1427406123

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 28 payments — averaging $70.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$555
  • Optos, Inc.$220
  • Johnson & Johnson Vision Care, Inc.$216
  • Aerie Pharmaceuticals, Inc.$183
  • AbbVie$153
  • Bausch & Lomb Americas Inc.$147
  • plus $497 from 4 others

What the payments were for

  • Food & beverage$1,84494%
  • Entertainment$1266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,970 in reported general payments places this provider in the 75th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$33,603
Medicare patients
136
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol130$33,509
RestasisCyclosporine41$31,280
RhopressaNetarsudil Mesylate87$29,507
VyzultaLatanoprostene Bunod56$22,795
LumiganBimatoprost62$15,421
RocklatanNetarsudil Mesylat/Latanoprost28$9,595
SimbrinzaBrinzolamide/Brimonidine Tart29$5,604
Brimonidine Tartrate82$3,723
Latanoprost360$2,227
Travoprost19$1,859
Prednisolone Acetate39$1,533
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,186
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$742
Dorzolamide Hcl43$610
Timolol Maleate73$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Restasis, Lumigan$153$80,211233 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$183$39,102115 claims
Bausch & Lomb Americas Inc.Vyzulta$147$22,79556 claims
AlconSimbrinza$555$5,60429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Lexington

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →